Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.
2.

The HSP90 inhibitor 17-AAG synergizes with doxorubicin and U0126 in anaplastic large cell lymphoma irrespective of ALK expression.

Georgakis GV, Li Y, Rassidakis GZ, Medeiros LJ, Younes A.

Exp Hematol. 2006 Dec;34(12):1670-9.

PMID:
17157164
3.

STAT1 is phosphorylated and downregulated by the oncogenic tyrosine kinase NPM-ALK in ALK-positive anaplastic large-cell lymphoma.

Wu C, Molavi O, Zhang H, Gupta N, Alshareef A, Bone KM, Gopal K, Wu F, Lewis JT, Douglas DN, Kneteman NM, Lai R.

Blood. 2015 Jul 16;126(3):336-45. doi: 10.1182/blood-2014-10-603738.

4.

Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma.

Christensen JG, Zou HY, Arango ME, Li Q, Lee JH, McDonnell SR, Yamazaki S, Alton GR, Mroczkowski B, Los G.

Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3314-22.

5.

Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)+ and ALK- anaplastic large-cell lymphoma.

Merkel O, Hamacher F, Laimer D, Sifft E, Trajanoski Z, Scheideler M, Egger G, Hassler MR, Thallinger C, Schmatz A, Turner SD, Greil R, Kenner L.

Proc Natl Acad Sci U S A. 2010 Sep 14;107(37):16228-33. doi: 10.1073/pnas.1009719107.

6.

Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas.

Piva R, Chiarle R, Manazza AD, Taulli R, Simmons W, Ambrogio C, D'Escamard V, Pellegrino E, Ponzetto C, Palestro G, Inghirami G.

Blood. 2006 Jan 15;107(2):689-97.

7.

Silibinin suppresses NPM-ALK, potently induces apoptosis and enhances chemosensitivity in ALK-positive anaplastic large cell lymphoma.

Molavi O, Samadi N, Wu C, Lavasanifar A, Lai R.

Leuk Lymphoma. 2016 May;57(5):1154-62. doi: 10.3109/10428194.2015.1068306.

PMID:
26133723
8.

IGF-IR tyrosine kinase interacts with NPM-ALK oncogene to induce survival of T-cell ALK+ anaplastic large-cell lymphoma cells.

Shi P, Lai R, Lin Q, Iqbal AS, Young LC, Kwak LW, Ford RJ, Amin HM.

Blood. 2009 Jul 9;114(2):360-70. doi: 10.1182/blood-2007-11-125658.

9.

Sonic hedgehog signaling pathway is activated in ALK-positive anaplastic large cell lymphoma.

Singh RR, Cho-Vega JH, Davuluri Y, Ma S, Kasbidi F, Milito C, Lennon PA, Drakos E, Medeiros LJ, Luthra R, Vega F.

Cancer Res. 2009 Mar 15;69(6):2550-8. doi: 10.1158/0008-5472.CAN-08-1808.

10.
11.

A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation.

Abate F, Todaro M, van der Krogt JA, Boi M, Landra I, Machiorlatti R, Tabbò F, Messana K, Abele C, Barreca A, Novero D, Gaudiano M, Aliberti S, Di Giacomo F, Tousseyn T, Lasorsa E, Crescenzo R, Bessone L, Ficarra E, Acquaviva A, Rinaldi A, Ponzoni M, Longo DL, Aime S, Cheng M, Ruggeri B, Piccaluga PP, Pileri S, Tiacci E, Falini B, Pera-Gresely B, Cerchietti L, Iqbal J, Chan WC, Shultz LD, Kwee I, Piva R, Wlodarska I, Rabadan R, Bertoni F, Inghirami G; European T-cell Lymphoma Study Group..

Leukemia. 2015 Jun;29(6):1390-401. doi: 10.1038/leu.2014.347.

12.

The expression and oncogenic effects of the embryonic stem cell marker SALL4 in ALK-positive anaplastic large cell lymphoma.

Wang P, Zhang JD, Wu F, Ye X, Sharon D, Hitt M, McMullen TP, Hegazy SA, Gelebart P, Yang J, Ma Y, Lai R.

Cell Signal. 2012 Oct;24(10):1955-63. doi: 10.1016/j.cellsig.2012.06.005.

PMID:
22743134
13.
14.
15.

The anaplastic lymphoma kinase controls cell shape and growth of anaplastic large cell lymphoma through Cdc42 activation.

Ambrogio C, Voena C, Manazza AD, Martinengo C, Costa C, Kirchhausen T, Hirsch E, Inghirami G, Chiarle R.

Cancer Res. 2008 Nov 1;68(21):8899-907. doi: 10.1158/0008-5472.CAN-08-2568.

16.
18.

The oncogenic JUNB/CD30 axis contributes to cell cycle deregulation in ALK+ anaplastic large cell lymphoma.

Atsaves V, Lekakis L, Drakos E, Leventaki V, Ghaderi M, Baltatzis GE, Chioureas D, Jones D, Feretzaki M, Liakou C, Panayiotidis P, Gorgoulis V, Patsouris E, Medeiros LJ, Claret FX, Rassidakis GZ.

Br J Haematol. 2014 Nov;167(4):514-23. doi: 10.1111/bjh.13079.

PMID:
25145835
19.

Targeting autophagy enhances the anti-tumoral action of crizotinib in ALK-positive anaplastic large cell lymphoma.

Mitou G, Frentzel J, Desquesnes A, Le Gonidec S, AlSaati T, Beau I, Lamant L, Meggetto F, Espinos E, Codogno P, Brousset P, Giuriato S.

Oncotarget. 2015 Oct 6;6(30):30149-64. doi: 10.18632/oncotarget.4999.

Supplemental Content

Support Center